

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN INSTITUTIONAL INC.
Petitioner,

v.

FRESENIUS KABI USA, LLC,
Patent Owner.

U.S. Patent No. 9,006,289 to Jiang et al.
Issue Date: April 14, 2015
Title: Levothyroxine Formulations
Case: IPR2017-00645

U.S. Patent No. 9,238,238 to Jiang et al.
Issue Date: October 27, 2015
Title: Levothyroxine Formulations
Case: IPR2017-00643

U.S. Patent No. 9,238,239 to Jiang et al.
Issue Date: October 27, 2015
Title: Levothyroxine Formulations
Case: IPR2017-00644

DECLARATION OF JAMES E. KIPP, PH.D

TABLE OF CONTENTS

I.	Introduction	1
II.	Background and Qualifications	2
III.	List of Materials Considered	8
IV.	Legal Standards	11
V.	Summary of Opinions	15
A.	Claims 1-21 of the '289 Patent Would Have Been Obvious	15
B.	Claims 1-30 of the '238 patent Would Have Been Obvious	15
C.	Claims 1-15 of the '239 patent would have been obvious	16
VI.	The Jiang Patents	17
VII.	Level of Ordinary Skill in the Art	23
VIII.	The Subject Matter of Claims 1-21 of the '289 Patent, Claims 1-30 of the '238 Patent, and Claims 1-15 of the '239 Patent Would Have Been Obvious	25
A.	Scope and Content of the Prior Art	25
i.	Levothyroxine Sodium Compositions	25
ii.	Instability of Levothyroxine Sodium Compositions	26
iii.	Mannitol was the Most Commonly Used Bulking Agent and was Used in Lyophilized Levothyroxine Sodium Compositions	34
iv.	Mannitol's Degradation of Moisture-Sensitive Compounds	37
B.	Obviousness Based on the Abbott Label, Brower, Baheti, and Collier	45
i.	Independent Claims of the Jiang Patents	45
a.	Independent Claims 1 and 14 of the '289 Patent	45
b.	Independent Claims 1, 11, and 21 of the '238 Patent	47
c.	Independent Claim 1 of the '239 Patent	49
d.	It Would Have Been Obvious to Use 100 Micrograms of Levothyroxine Sodium	49

	e.	It Would Have Been Obvious to Reduce the Amount of Mannitol Below 10 Milligrams	50
ii.		Dependent Claims of the '289 Patent	74
	a.	Amount of Levothyroxine Sodium: Claims 2 and 3	74
	b.	Amount of Mannitol: Claims 2, 3, and 15	74
	c.	Phosphate Buffer and Amount: Claims 4, 9, and 16.....	75
	d.	Lyophilization Process: Claim 5, 10, and 17	79
	e.	Amount of Levothyroxine Sodium Converted to Liothyronine: Claims 6–8, 11–13, and 18–21	80
iii.		Dependent Claims of the '238 Patent	88
	a.	Amount of Levothyroxine Sodium Converted to Liothyronine: Claims 2, 3, 12, 13, 22, and 23	88
	b.	Amount of Mannitol: Claim 4, 14, and 24.....	90
	c.	Pharmaceutically Acceptable Liquid Carrier: Claims 5, 15, and 25	90
	d.	Concentration of Levothyroxine in Pharmaceutical Solution: Claims 6, 16, and 26	91
	e.	Method of Providing Levothyroxine to a Patient in Need: Claims 7, 17, and 27	92
	f.	Dosage of Levothyroxine Sodium: Claims 8, 9, 18, 19, 28, and 29	92
	g.	Phosphate Buffer: Claim 10, 20, and 30.....	93
iv.		Dependent Claims of the '239 Patent	94
	a.	Amount of Levothyroxine Sodium Converted to Liothyronine: Claims 2-5	94
	b.	Amount of Mannitol: Claim 6	99
	c.	Phosphate Buffer and/or Amount: Claims 7 and 8	100
	d.	Levothyroxine Sodium: Claim 9	100
	e.	Pharmaceutically Acceptable Liquid Carrier: Claim 10	101
	f.	Concentration of Levothyroxine in Pharmaceutical Solution: Claim 11	101
	g.	pH of the Solution: Claim 12	101
	h.	Method of Providing Levothyroxine to a Patient in Need: Claim 13	108
	i.	Dosage of Levothyroxine Sodium: Claims 14 and 15.....	108
C.		Obviousness Based on the APP Label, Brower, Baheti, and Collier.....	109
	i.	Independent Claims of the Jiang Patents	109

a.	Independent Claims 1 and 14 of the '289 Patent	109
b.	Independent Claims 1, 11, and 21 of the '238 Patent.....	111
c.	Independent Claim 1 of the '239 Patent	112
d.	It Would Have Been Obvious to Reduce the Amount of Mannitol Below 10 Milligrams	113
ii.	Dependent Claims of the '289 Patent	120
a.	Amount of Levothyroxine Sodium: Claims 2 and 3	120
b.	Amount of Mannitol: Claims 2, 3, and 15	120
c.	Phosphate Buffer and Amount: Claims 4, 9, and 16....	121
d.	Lyophilization Process: Claim 5, 10, and 17	123
e.	Amount of Levothyroxine Sodium Converted to Liothyronine: Claims 6–8, 11–13, and 18–21	123
iii.	Dependent Claims of the '238 Patent	124
a.	Amount of Levothyroxine Sodium Converted to Liothyronine: Claims 2, 3, 12, 13, 22, and 23	124
b.	Amount of Mannitol: Claim 4, 14, and 24.....	125
c.	Pharmaceutically Acceptable Liquid Carrier: Claims 5, 15, and 25	125
d.	Concentration of Levothyroxine in Pharmaceutical Solution: Claims 6, 16, and 26	126
e.	Method of Providing Levothyroxine to a Patient in Need: Claims 7, 17, and 27	127
f.	Dosage of Levothyroxine Sodium: Claims 8, 9, 18, 19, 28, and 29	127
g.	Phosphate Buffer: Claim 10, 20, and 30.....	128
iv.	Dependent Claims of the '239 Patent	128
a.	Amount of Levothyroxine Sodium Converted to Liothyronine: Claims 2-5	128
b.	Amount of Mannitol: Claim 6.....	130
c.	Phosphate Buffer and/or Amount: Claims 7 and 8	130
d.	Levothyroxine Sodium: Claim 9	131
e.	Pharmaceutically Acceptable Liquid Carrier: Claim 10	131
f.	Concentration of Levothyroxine in Pharmaceutical Solution: Claim 11	131
g.	pH of the Solution: Claim 12	132
h.	Method of Providing Levothyroxine to a Patient in Need: Claim 13.....	132

	i.	Dosage of Levothyroxine Sodium: Claims 14 and 15.....	132
D.		Obviousness Based on the Abbott Label, APP Label, Brower, Baheti, and Collier	133
	i.	Independent Claims of the Jiang Patents	133
	a.	It Would Have Been Obvious to Reduce the Amount of Mannitol Below 10 Milligrams	134
	ii.	Dependent Claims of the '289 Patent	135
	a.	Amount of Levothyroxine Sodium: Claims 2 and 3	135
	b.	Amount of Mannitol: Claims 2, 3, and 15	135
	c.	Phosphate Buffer and Amount: Claims 4, 9, and 16....	136
	d.	Lyophilization Process: Claim 5, 10, and 17	137
	e.	Amount of Levothyroxine Sodium Converted to Liothyronine: Claims 6–8, 11–13, and 18–21	137
	iii.	Dependent Claims of the '238 Patent	139
	a.	Amount of Levothyroxine Sodium Converted to Liothyronine: Claims 2, 3, 12, 13, 22, and 23	139
	b.	Amount of Mannitol: Claim 4, 14, and 24.....	139
	c.	Pharmaceutically Acceptable Liquid Carrier: Claims 5, 15, and 25	140
	d.	Concentration of Levothyroxine in Pharmaceutical Solution: Claims 6, 16, and 26	140
	e.	Method of Providing Levothyroxine to a Patient in Need: Claims 7, 17, and 27	141
	f.	Dosage of Levothyroxine Sodium: Claims 8, 9, 18, 19, 28, and 29	141
	g.	Phosphate Buffer: Claim 10, 20, and 30.....	142
	iv.	Dependent Claims of the '239 Patent	143
	a.	Amount of Levothyroxine Sodium Converted to Liothyronine: Claims 2-5	143
	b.	Amount of Mannitol: Claim 6.....	144
	c.	Phosphate Buffer and/or Amount: Claims 7 and 8	144
	d.	Levothyroxine Sodium: Claim 9	145
	e.	Pharmaceutically Acceptable Liquid Carrier: Claim 10	145
	f.	Concentration of Levothyroxine in Pharmaceutical Solution: Claim 11	146
	g.	pH of the Solution: Claim 12	146
	h.	Method of Providing Levothyroxine to a Patient in Need: Claim 13	147

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.